Viva Biotech collaborates with NVIDIA to advance AI-driven drug discovery

Reuters09:00
<a href="https://laohu8.com/S/VBIZF">Viva Biotech</a> collaborates with NVIDIA to advance AI-driven drug discovery

Viva Biotech is working with NVIDIA to optimize the Proteina-Complexa model for designing mini-binders targeting the ActRIIA receptor. The collaboration uses NVIDIA BioNeMo within Viva Biotech’s “Lab-in-the-Loop” workflow, combining computational design with protein production and biophysical evaluation. Viva Biotech said it is providing feedback from its AI-based sequence selection to improve the Proteina-Complexa model.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VIVA Biotech Holdings published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603162100PR_NEWS_USPR_____CN10658) on March 17, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment